SCHEMBL5863407

SCHEMBL5863407

CCOC(=O)c1ccn2nc(C)n(Cc3ccccc3)c(=O)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 4/20 0.48
KMT2A Q03164 2/20 0.47
HPGD P15428 2/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CNR1 P21554 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
MAPK1 P28482 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863440 0.78 KIF11 (0.48) ALDH1A1KDM4EHPGDMAPK1LMNA
SCHEMBL5863347 0.76 KMT2A (0.42) ALDH1A1KDM4EKMT2ASMN1; SMN2ADORA3
SCHEMBL5863203 0.72 KMT2A (0.39) ALDH1A1KDM4EKMT2AHPGDSMN1; SMN2
SCHEMBL9894331 0.71 MAPT (0.56) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL12502932 0.70 NOTUM (0.55) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL17430001 0.70 MEN1 (0.52) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL554285 0.70 NOTUM (0.70) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL18397259 0.70 CYP1A2 (0.49) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL18397505 0.69 KMT2A (0.43) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL5863322 0.69 ALDH1A1 (0.44) TSHRALDH1A1KDM4EKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030118-B2 Pyrrolotriazinone compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-18 US disclosed
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents BRISTOL-MYERS SQUIBB COMPANY 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents CCNB1, NUMA1, CCNA1 TSHR 4587/4885ALDH1A1 1027/4885KDM4E 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.